RUNX1 and myelodysplastic syndrome: Recently, AMLs harboring eight sAML mutations and RUNX1 mutation have been categorized as AML with MDS-related gene mutations in the International Consensus Classification (ICC) [3] and the adverse-risk group in the 2022 ELN risk classification [5].